Recently, Gao et al. [5] have demonstrated the in vitro efficacy of C75, a Fatty Acid Synthase (FAS) inhibitor that induces growth arrest in several HCC derived cell lines, offering a promising novel therapy that explores another frontier for hepatocellular cancer treatment, i.e. metabolic manipulation. This evidence concerns the gene FASN and hepatocellular carcinoma.